The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.30
Bid: 4.10
Ask: 4.50
Change: 0.00 (0.00%)
Spread: 0.40 (9.756%)
Open: 4.30
High: 4.30
Low: 4.30
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First Order For Ecovelex

16 Aug 2023 07:00

RNS Number : 4283J
Eden Research plc
16 August 2023
 

16 August 2023

 

 

Eden Research

("Eden" or "the Company")

 

Eden receives its first order for Ecovelex®

 

Eden's new sustainable seed treatment product helps farmers safely repel birds.

 

Eden Research plc (AIM: EDEN; OTCQB: EDNSF), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, today announces that it has received its first commercial order for Ecovelex.

 

Developed by Eden Research over the past three years, Ecovelex represents a new entrant into the seed treatment market and is intended to replace conventional chemicals that are facing significant regulatory pressures in the EU and UK. This new product was developed to tackle crop destruction caused by birds, a major cause of losses in maize and other crops.

 

Until full authorisation is received, the use of Ecovelex to treat seeds this year is contingent upon certain countries granting emergency use authorisation. Unless, and until, emergency use approvals are granted, it is difficult to anticipate the full demand in the short term.

 

Following the successful fundraise announced by the Company on 28 July 2023, production of Ecovelex is now underway to fulfil this initial order. It is expected that the order will be shipped towards the end of the year so that, in the event of receipt of relevant regulatory approvals, it will be available in time for the seed treatment window for the 2024 growing season.

 

Sean Smith, Eden CEO, said: "I'm pleased to have received our first commercial order for Ecovelex and am pleased to report that production is underway here in the UK to fulfil the order.

 

At this point in the year, and without visibility on emergency use authorisations, it is not possible to provide guidance on the overall potential financial impact of the Ecovelex sales, however, this order and initial production is clearly a positive step forward for maize growers and the Company."

 

 

 

 

 

 

 

For further information contact:

 

Eden Research plc

Sean SmithAlex Abrey

 

www.edenresearch.com

+44 (0) 1285 359 555

 

 

Cenkos Securities plc (NOMAD and broker to Eden Research plc)

Giles Balleny / Max Gould (corporate finance)Michael Johnson (sales)

 

+44 (0) 20 7397 8900

Hawthorn Advisors (Financial PR to Eden Research plc)

Simon Woods

Felix Meston

eden@hawthornadvisors.com

 

 

Notes to Editors:

 

About Eden

 

Eden is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information, please visit: www.edenresearch.com.

 

Follow Eden on LinkedInTwitter and YouTube

 

 

About Ecovelex

 

Ecovelex is new entrant into the seed treatment market developed to tackle crop destruction caused by birds, a major cause of losses in maize and other crops and is intended to replace conventional chemicals that are facing significant regulatory pressures in the EU and UK.

 

Ecovelex works by affecting the bird's olfactory system, creating an unpleasant taste or odour that repels the birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry and formulated using the Company's Sustaine® microencapsulation technology, supporting farmers as they strive to meet consumer and regulator demands for more sustainable agriculture.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTNKPBBKBKBKFD
Date   Source Headline
13th Jul 201810:23 amRNSDirector/PDMR Shareholding
21st Jun 20184:44 pmRNSResult of AGM
21st Jun 20187:00 amRNSAGM Statement
19th Jun 20187:00 amRNSDirector/PDMR Shareholding
14th Jun 20187:00 amRNSRegulatory Progress Update
30th May 20182:30 pmRNSPosting of Annual Report & Notice of AGM
10th May 20185:04 pmRNSDirector/PDMR Shareholding
8th May 20187:00 amRNSExercise of Options
20th Mar 20187:00 amRNSPreliminary results
11th Jan 20187:00 amRNSYear-end Trading Statement
12th Dec 20177:00 amRNSRegulatory Progress Update
29th Sep 201711:15 amRNSHalf-year Report - Replacement
29th Sep 20177:30 amRNSAdoption of New LTIP and Grant of Awards
29th Sep 20177:01 amRNSBoard Changes
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:00 amRNSApproval of MevaloneT in Portugal
1st Sep 20177:00 amRNSNotice of Results
30th Jun 20175:14 pmRNSHolding(s) in Company
30th Jun 201712:29 pmRNSResult of AGM
30th Jun 20177:43 amRNSAGM Statement
30th Jun 20177:39 amRNSCompletion of Placing & Subscription
30th Jun 20177:00 amRNSSipcam agreements, investment and proposed placing
29th Jun 20179:43 amRNSNew terms agreed with UMMS
5th Jun 20173:14 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20177:00 amRNSFinal Results
11th May 20179:00 amRNSEden Research on BBC Radio 4's You & Yours
29th Mar 20177:00 amRNSExtension of patent protection in Greece
8th Mar 20172:40 pmRNSVoting Rights, Warrants and Options Outstanding
23rd Jan 20172:00 pmRNSPrice Monitoring Extension
23rd Jan 20177:00 amRNSFungicide product approved for sale in France
21st Dec 20167:01 amRNSTrading update
21st Dec 20167:00 amRNSEastman commercialisation agreement for nematicide
27th Sep 20167:00 amRNSHalf-year Report
28th Jun 201612:28 pmRNSResult of AGM
28th Jun 20167:00 amRNSAGM Statement
15th Jun 20167:00 amRNSLabel extensions for 3AEY in Spain and Greece
7th Jun 20167:00 amRNSPosting of Annual Report & Notice of AGM
26th May 20163:36 pmRNSDirector/PDMR Shareholding
24th May 20167:00 amRNSFinal Results
11th Apr 20169:31 amRNSHolding(s) in Company
30th Mar 20167:00 amRNSPlacing to raise £2.6m
22nd Feb 20167:00 amRNSApproval of 3AEY in Spain
11th Feb 20167:00 amRNSApproval of 3AEY in Italy
10th Feb 20167:00 amRNSFirst shipment of MevaloneT (3AEY) to Greece
21st Jan 20167:00 amRNSExercise of options
14th Jan 20167:00 amRNSFurther progress with EU product approvals
16th Nov 20157:00 amRNSKenya approval & first commercial-scale order
26th Oct 20157:00 amRNSAppointment of Nominated Adviser and Broker
24th Sep 20157:00 amRNSCollaboration and Licence Agreement Signed
15th Sep 20157:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.